Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 15Terminated 3Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Sarcoma 18Breast 4Genitourinary 3CNS 3Thoracic 2Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Gynecologic 2Gastrointestinal 2Dermatologic 2Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 549Lung Neoplasms 312Small Cell Lung Carcinoma 87Colorectal Neoplasms 71Melanoma 68Breast Neoplasms 60Neoplasms 55Ovarian Neoplasms 47Neoplasm Metastasis 45Carcinoma, Renal Cell 45Squamous Cell Carcinoma of Head and Neck 43Pancreatic Neoplasms 39Stomach Neoplasms 37Triple Negative Breast Neoplasms 31Head and Neck Neoplasms 30Esophageal Neoplasms 28Endometrial Neoplasms 25Prostatic Neoplasms 24Uterine Cervical Neoplasms 23Urinary Bladder Neoplasms 23Brain Neoplasms 22Colonic Neoplasms 21Mesothelioma 20Mesothelioma, Malignant 18Carcinoma, Hepatocellular 18Sarcoma 16Carcinoma, Transitional Cell 15Adenocarcinoma of Lung 15Lung Diseases 14NSCLC 13

Interventions

liposomal doxorubicin 1Taxes 1Paclitaxel 1Observation 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Bone Neoplasms × Thoracic × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmSarcomaThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡